Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Mar 2022
Better care and treatment for Australians with blood cancer
15 March 2022 - Australians with blood cancer will receive improved treatment and care through new and continued funding from the ...
Posted by Michael Wonder on 15 Mar 2022
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
Posted by Michael Wonder on 15 Mar 2022
FDA approves first generic of Symbicort to treat asthma and COPD
15 March 2022 - Agency supports development of complex generic drug-device combination product to improve competition and access to more affordable ...
Posted by Michael Wonder on 15 Mar 2022
Prolonged price negotiation for Kymriah devastates leukaemia patients
15 March 2022 - Drained by dragging price negotiations between Novartis and the Government for breakthrough cancer treatment Kymriah (tisagenlecleucel), ...
Posted by Michael Wonder on 15 Mar 2022
BeiGene and Medison announce approval and national reimbursement in Israel for Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinaemia
15 March 2022 - Second regulatory approval for Brukinsa in Israel. ...
Posted by Michael Wonder on 15 Mar 2022
What’s really driving drug costs?
15 March 2022 - Despite the wonders accomplished by the biopharmaceutical industry in providing us vaccines and therapeutants to get us ...
Posted by Michael Wonder on 15 Mar 2022
Myrtelle receives FDA fast track, rare paediatric disease, and orphan drug designations for its proprietary gene therapy for the treatment of Canavan disease
15 March 2022 - Myrtelle today announced that the U.S. FDA has granted fast track, rare paediatric disease and orphan ...
Posted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...
Posted by Michael Wonder on 15 Mar 2022
Single dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration
14 March 2022 - Novel paediatric relapse prevention treatment marks a major contribution towards malaria elimination efforts. ...
Posted by Michael Wonder on 15 Mar 2022
Collider bias
14 March 2022 - Bias is a systematic, non-random error in the estimation of a treatment effect or the effect of ...
Posted by Michael Wonder on 15 Mar 2022
1 April 2022 price disclosure confirmed prices
15 March 2022 - Confirmed 1 April 2022 prices resulting from the 2022 April cycle of price disclosure have now been ...
Posted by Michael Wonder on 14 Mar 2022
Teduglutide for treating short bowel syndrome
11 March 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using teduglutide ...
Posted by Michael Wonder on 14 Mar 2022
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease
11 March 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using imlifidase ...
Posted by Michael Wonder on 14 Mar 2022
Incyte announces U.S. FDA has extended the supplemental new drug application review period for ruxolitinib cream (Opzelura) for the treatment of vitiligo
14 March 2022 - Incyte announced today that the U.S. FDA has extended the review period for the supplemental new ...
Posted by Michael Wonder on 14 Mar 2022
Corium receives FDA approval of Adlarity (donepezil transdermal system) for treatment of patients with Alzheimer's disease
14 March 2022 - First and only once weekly patch for convenient, well-tolerated delivery of most used drug for treatment of ...